Effector reports Phase I/II data for eFT508 in hematological malignancies

Effector Therapeutics Inc. (San Diego, Calif.) reported data from 10 evaluable patients with hematological malignancies in a Phase I/II trial showing that eFT508 led to one partial response in a patient with non-germinal center B cell-like diffuse large B cell lymphoma (DLBCL), plus four cases of stable disease. eFT508 was generally well tolerated. Data were presented at the American Society of Hematology meeting in Atlanta in December.

The open-label, dose-escalation, U.S. trial is enrolling about 96 patients with hematological malignancies and is evaluating maximum tolerated dose (MTD), recommended dose and overall response rate (ORR)...